Results 141 to 150 of about 53,318 (258)
First experiences in the implementation of rivaroxaban in patients with pulmonary thromboembolism who received thrombolytic therapy [PDF]
Slobodan Obradović +9 more
openalex +1 more source
This study shows that overweight and obese patients with atrial fibrillation experience improved outcomes when treated with DOACs compared with VKAs. Specifically, DOAC use was associated with lower risks of all‐cause mortality and cardiovascular events.
Danilo Menichelli +58 more
wiley +1 more source
ABSTRACT Introduction Obstructive sleep apnea (OSA) is a common risk factor for the development and progression of atrial fibrillation (AF). Whether catheter ablation for AF management in patients with coexisting OSA yields survival benefit remains unclear.
Ghassan Bidaoui +16 more
wiley +1 more source
UV Spectrophotometric Method for Determination of the Dissolution Profile of Rivaroxaban
Mustafa Çelebi̇er +3 more
openalex +1 more source
Managing a Rivaroxaban Bleed: Understanding the Difficulties in Acute Reversal of the New Oral Anticoagulants through a Case Report [PDF]
Naveen Nannapaneni +3 more
openalex +1 more source
Periprocedural Off-label Use of Rivaroxaban in Patient with Atrial Fibrillation and a Persistent Left Atrial Appendage Thrombus Despite Standard Anticoagulation Therapy: A Case Report [PDF]
Archil Chukhrukidze, Zviad Kereselidze
openalex +1 more source
Our findings highlight that preoperative FMR assessment could reliably benefit surgeons in patient education and surgical timing determination, as FMR demonstrates superior predictive capacity compared to BMI for both complications and 12‐month patient‐reported outcomes following knee arthroplasty.
Long Zhao +5 more
wiley +1 more source
Molecular basis of water sorption behaviour of rivaroxaban–malonic acid cocrystal [PDF]
Dnyaneshwar P. Kale +5 more
openalex +1 more source
Formulation and Evaluation of Cyclodextrin Loaded Rivaroxaban Fast Dissolving Tablets
Trinadha Rao M +7 more
openalex +1 more source

